Figure 3.

Anoctamin 1 (ANO1) antagonism leads to a reduction in human uterine smooth muscle (USM) contractility. A, Experimental design outline of functional organ bath recordings. B, Representative tracings of oxytocin-induced (EC85) contractions in human USM with treatment of vehicle (0.1% dimethyl sulfoxide (DMSO)), 50 μM benzbromarone, and 500 μM benzbromarone. C, Sigmoidal dose–response curve demonstrating the percent reduction in integral force (gram × seconds) at different concentrations of benzbromarone (7 patients; with n = 5 to 7 strips at each concentration tested). IC₅₀ of benzbromarone on reduction in force from an EC85 oxytocin-induced contraction of human USM is 45 μM. D, Benzbromarone significantly decreases integral force of oxytocin-induced (EC85) human USM contractions in a dose-dependent manner. The lowest effective dose of benzbromarone was 25 μM (***P < .001; ns, not significant). E, Percentage changes in frequency measured at 2 intervals (30 and 60 minutes) is decreased by benzbromarone in a concentration-dependent manner (0-500 μM). F, Slopes of tracings from (E) were calculated and compiled. Benzbromarone decreases oxytocin-induced USM contractile frequency in a dose-dependent manner. The lowest effective concentration of benzbromarone on frequency was 10 μM. (*P < .05, ***P < .001).